childhood absence epilepsy
Information
- Disease name
- childhood absence epilepsy
- Disease ID
- DOID:1825
- Description
- "A childhood electroclinical syndrome that is characterized by brief and frequent absence seizures in children with age of onset between four and ten years." [url:http\://en.wikipedia.org/wiki/Childhood_absence_epilepsy]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00088452 | Completed | Phase 3 | Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study | July 2004 | August 31, 2016 |
| NCT00361010 | Completed | N/A | A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy | December 2006 | December 2007 |
| NCT00393666 | Completed | Why Are Patients With Absence Seizures Absent? A Brain Imaging Study | September 2006 | September 2015 | |
| NCT00041951 | Completed | Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study | December 1998 | July 2014 | |
| NCT05109234 | Enrolling by invitation | Phase 3 | A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | March 30, 2022 | September 27, 2024 |
| NCT06315322 | Not yet recruiting | Phase 3 | A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | June 14, 2024 | February 28, 2029 |
| NCT04666610 | Recruiting | Phase 3 | A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy | July 29, 2021 | February 25, 2026 |
| NCT06310772 | Recruiting | Assessing Comorbidities in Epilepsy Using Eye Movement Recordings | April 15, 2024 | March 1, 2025 | |
| NCT03355300 | Terminated | Phase 2 | Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | February 20, 2018 | June 28, 2019 |
| NCT06153186 | Terminated | Phase 2 | Flunarizine for Treatment Resistant Absence Epilepsy | September 20, 2019 | May 26, 2023 |
| NCT03336242 | Terminated | Phase 2 | Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | December 29, 2017 | May 29, 2019 |
- Disase is a (Disease Ontology)
- DOID:0050704
- Cross Reference ID (Disease Ontology)
- MESH:D004832
- Cross Reference ID (Disease Ontology)
- NCI:C3023
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:163596002
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0014553
- Exact Synonym (Disease Ontology)
- petit mal seizure
- Exact Synonym (Disease Ontology)
- pyknolepsy
- Disase Synonym (Disease Ontology)
- absence seizure
- OrphaNumber from OrphaNet (Orphanet)
- 64280